Medical Research Council

British Technology Group Limited

The Institute of Cancer Research: Royal Cancer Hospital

Genetic Therapy, Inc.

Mary Katharine Collins

Francois-Loic Cosset

Robin Anthony Weiss

Stephen James Russell

Frances Joanne Morling

Yasuhiro Takeuchi

Michael Pensiero

Frances Joanne Bullough

Manoochehr Tavassoli

Sydney Shall

Farzin Farzaneh

The invention relates to a recombinant viral particle capable of delivering a nucleic acid to mammalian cells, the particle including a member of a first specific binding pair capable of binding to a first receptor expressed on the surface of a cell so as to cause infection thereof, and a surface-exposed member of a second specific binding pair capable of binding to a second receptor generally not expressed on the surface of the cell, such that binding of the viral particle to the second receptor via the member of the second specific binding pair inhibits infection of the cell by the viral particle.

Delivery of nucleic acids

Retroviral which are resistant to inactivation by human serum. The retroviral vectors are produced in a cell line which is resistant to lysis by human serum, such cell lines including the HOS, Mv-1-Lu, HT1080, TE671, and human 293 cell lines, as well as cell lines derived therefrom. Such retroviral vectors are especially useful as in vivo gene delivery vehicles.

Retroviral vectors produced by producer cell lines resistant to lysis by

The use of a poly(ADP-ribose) polymerase inhibitor for the treatment of a subject against infection by a virus, in which the viral or proviral DNA integrates into the chromosome or chromosomes during its replication cycle.

Inhibition of viral infection

Growing community of inventors

London, United Kingdom

Mary Katharine Collins